chronic thromboembolic pulmonary hypertension


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.
Related to chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy

chronic thromboembolic pulmonary hypertension

persistent pulmonary hypertension caused by obstruction of a major pulmonary artery by an unresolved embolus or multiple small pulmonary emboli.

chronic thromboembolic pulmonary hypertension

Abbreviation: CTEPH
Pulmonary HTN that results from the migration of blood clots (usually from the lower extremities) into the lungs. Elevated BP in the lungs gradually overloads the right ventricle and causes right-sided heart failure.

Symptoms

Symptoms usually include shortness of breath, esp. during exercise.

Treatment

The disease, when identified, may be treated with surgical removal of blood clots.

See also: hypertension
References in periodicals archive ?
Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism.
Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism.
Diagnostic advances and opportunities in chronic thromboembolic pulmonary hypertension.
Findings on Submillimeter MDCT Are Predictive of Operability in Chronic Thromboembolic Pulmonary Hypertension.
State-of-the art imaging techniques in chronic thromboembolic pulmonary hypertension.
Successful surgical intervention in severe chronic thromboembolic pulmonary hypertension.
Risk factors for chronic thromboembolic pulmonary hypertension.
Predictors of mortality outcome of inoperable chronic thromboembolic pulmonary hypertension
Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension.
Riociguat has been approved under the trade name AdempasA by Health Canada for the treatment of inoperable, or persistent /recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgery in adult patients with WHO Functional Class II or III pulmonary hypertension in September.
The results of the CHEST-2 trial support the positive data of the pivotal CHEST-1 trial, showing long-term safety and sustained clinical benefits in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).

Full browser ?